Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Monte Rosa Therapeutics in a research report issued on Wednesday, March 12th. Lifesci Capital analyst O. Mccammon anticipates that the company will post earnings per share of ($2.00) for the year. Lifesci Capital has a "Outperform" rating and a $19.00 price target on the stock. The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.49) per share. Lifesci Capital also issued estimates for Monte Rosa Therapeutics' Q4 2024 earnings at ($0.66) EPS.
Separately, Wells Fargo & Company cut shares of Monte Rosa Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $14.00 to $11.00 in a research note on Thursday, December 19th.
Get Our Latest Research Report on Monte Rosa Therapeutics
Monte Rosa Therapeutics Stock Performance
Monte Rosa Therapeutics stock traded down $0.06 during trading on Friday, reaching $6.67. The company had a trading volume of 851,903 shares, compared to its average volume of 913,675. The firm's 50-day simple moving average is $6.14 and its 200 day simple moving average is $6.77. Monte Rosa Therapeutics has a 1-year low of $3.21 and a 1-year high of $12.40. The firm has a market capitalization of $409.78 million, a PE ratio of -3.64 and a beta of 1.50.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GLUE. Tower Research Capital LLC TRC lifted its holdings in Monte Rosa Therapeutics by 192.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company's stock valued at $38,000 after purchasing an additional 3,584 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Monte Rosa Therapeutics by 10,665.5% during the 4th quarter. GAMMA Investing LLC now owns 5,921 shares of the company's stock worth $41,000 after acquiring an additional 5,866 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth $43,000. Virtus ETF Advisers LLC purchased a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth $63,000. Finally, Intech Investment Management LLC purchased a new position in shares of Monte Rosa Therapeutics during the 3rd quarter worth $77,000. Hedge funds and other institutional investors own 79.96% of the company's stock.
About Monte Rosa Therapeutics
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Stories
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
